

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Neutrophil elastase (NE; ELA-2); cyclin E (CCNE)	<i>In vitro</i> studies suggest a vaccine based on a peptide that NE cleaves from CCNE could help treat breast cancer. In breast cancer cell lines, NE cleaved full-length CCNE, which led to an increase in cell surface expression of CCNE ₁₄₄₋₁₅₂ compared with that seen using a control protease. In breast cancer cell lines pretreated with NE, compared with non-pretreated cell lines, primary CCNE ₁₄₄₋₁₅₂ -specific T cells increased cancer cell death. Planned work includes a Phase I trial of a CCNE ₁₄₄₋₁₅₂ vaccine to treat breast cancer. SciBX 5(20); doi:10.1038/scibx.2012.515 Published online May 17, 2012	Patented by The University of Texas MD Anderson Cancer Center; available for licensing	Mittendorf, E.A. <i>et al. Cancer Res.</i> ; published online May 7, 2012; doi:10.1158/0008-5472.CAN-11-4135 Contact: Elizabeth A. Mittendorf, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: eamitten@mdanderson.org Contact: Jeffrey J. Mollred, same affiliation as above e-mail: jmollred@mdanderson.org